Two more survivors in every hundred, and the gap is widening: six-year breast cancer results

Professor Im Seock-ah of Seoul National University Hospital walked through six-year results from the NATALEE trial at Europe's ESMO cancer congress with a simple way to picture them: about two more survivors for every 100 patients. The trial tested adding the drug Kisqali to standard hormone therapy for people whose early breast cancer had been removed by surgery, aiming to stop it ever returning. At six years, overall survival favoured the combination by 2.1 percentage points — a gap that grew from 1.2 points at five years, suggesting the benefit builds with time. For a cancer caught early, a widening gap is exactly what doctors hope to see.

SDG 3 · Good health and well-being — Mechanism: tech innovation